📗 Cite This Artifact
Korean Biotech Companies in Neurodegeneration
Overview
Overview
South Korea has emerged as a significant player in the global biotechnology landscape, with a rapidly expanding pharmaceutical sector focused on developing treatments for neurodegenerative diseases. The country combines advanced biotechnology capabilities with strong manufacturing infrastructure, creating a unique ecosystem for drug development targeting Alzheimer's disease, Parkinson's disease, and related conditions["1"].
South Korea faces a significant neurodegenerative disease burden. The country has one of the fastest aging populations globally, with approximately 10 million individuals over 65 years of age as of 2023. Alzheimer's disease affects approximately 800,000-1 million Koreans, while Parkinson's disease affects approximately 150,000-200,000 individuals["2"][3]. This demographic challenge has catalyzed substantial investment in neurodegeneration research and development.
Korean pharmaceutical companies have developed sophisticated capabilities across multiple therapeutic modalities, including small molecule therapeutics, biologics, cell therapy, and novel drug delivery systems. The Korean government's strong support for biotechnology R&D, through agencies like the Ministry of Food and Drug Safety (MFDS) and the Ministry of Trade, Industry and Energy, has created a favorable environment for innovation["4"][5].
Key Companies
Daewoong Pharmaceutical (대웅제약)
Daewoong Pharmaceutical (KRX: 005930) is one of Korea's largest pharmaceutical companies, headquartered in Seongnam, Gyeonggi-do. Founded in 1968, Daewoong has evolved into a diversified healthcare company with significant R&D capabilities in neuroscience[6].
Company Profile
| Attribute | Details |
|-----------|---------|
| Founded | 1968 |
| Headquarters | Seongnam, South Korea |
| Market Cap | ~₹1.5 trillion KRW (2024) |
| Employees | 3,500+ |
| Manufacturing | FDA, EMA, MFDS approved facilities |
| Global Markets | 80+ countries |
Neuroscience Pipeline
Daewoong has established a dedicated CNS research division focusing on neurodegenerative diseases:
Alzheimer's Disease Program
- Target: Amyloid-beta aggregation inhibitors
- Stage: Preclinical/Phase 1
- Mechanism: Novel small molecule inhibitors of Aβ oligomerization
- Status: IND-enabling studies
The company is developing DWP213388, a novel BACE1 (Beta-site APP Cleaving Enzyme 1) inhibitor that reduces amyloid-beta production. BACE1 inhibition represents a disease-modifying approach targeting the upstream production of toxic Aβ species[6].
Parkinson's Disease Program
- Target: Alpha-synuclein aggregation
- Stage: Discovery
- Mechanism: Small molecule modulators preventing toxic aggregation
- Approach: Focus on intracellular aggregation inhibitors
Daewoong is also developing DWP590, a novel dopamine D1 receptor agonist for Parkinson's disease symptom management, with potential disease-modifying properties through neurotrophic effects[6].
Research Collaborations
Daewoong maintains partnerships with:
- Seoul National University (SNU) — CNS research collaboration
- Korea Institute of Science and Technology (KIST) — Drug discovery
- International partnerships with global pharma for clinical development
Manufacturing Capabilities
Daewoong operates state-of-the-art manufacturing facilities:
- API manufacturing: Multi-ton scale synthesis capabilities
- Formulation: Oral solids, injectables, topical
- Quality systems: US FDA, EMA, MFDS compliance
- CDMO services: Contract manufacturing for global partners
JW Pharmaceutical (JW제약)
JW Pharmaceutical (KRX: 001720) is a Korean pharmaceutical company focused on innovative drug development, particularly in CNS and oncology. Headquartered in Seoul, JW has built a reputation for advancing novel therapeutics through clinical development[7].
Company Profile
| Attribute | Details |
|-----------|---------|
| Founded | 1945 |
| Headquarters | Seoul, South Korea |
| Focus Areas | CNS, Oncology, Immunology |
| R&D Investment | ~15% of revenue |
| Pipeline | 15+ programs in development |
CNS Pipeline
Parkinson's Disease
- JWH-201: Novel adenosine A2A receptor antagonist
- Stage: Phase 2
- Indication: Parkinson's disease with motor complications
- Mechanism: Selective A2A antagonism for motor symptom control
- JWH-301: DOPA decarboxylase inhibitor
- Stage: Phase 1
- Indication: Adjunctive therapy with levodopa
- Advantage: Enhanced levodopa brain delivery
- JWH-401: Novel tau aggregation inhibitor
- Stage: Preclinical
- Target: Tau pathology in AD
- Mechanism: Prevents tau filament formation
- JWH-501: Neuroprotective agent
- Stage: Discovery
- Mechanism: Mitochondrial protection, oxidative stress reduction
Academic Partnerships
JW Pharmaceutical collaborates extensively with Korean academic institutions:
- Seoul National University — Clinical trials, translational research
- Korea University — CNS basic research
- Yonsei University — Drug discovery and pharmacology
Hanmi Pharmaceutical (한미약품)
Hanmi Pharmaceutical (KRX: 128940) is a leading Korean pharmaceutical company with a strong focus on novel drug development, particularly in metabolic diseases and CNS disorders[8].
Company Profile
| Attribute | Details |
|-----------|---------|
| Founded | 1973 |
| Headquarters | Seoul, South Korea |
| Focus | Innovative drugs, biosimilars |
| R&D Investment | ~20% of revenue |
| Patents | 1,000+ globally |
CNS Pipeline
Alzheimer's Disease
- HM61713: BACE inhibitor
- Stage: Phase 2 (discontinued in 2018, pipeline repositioning)
- Notes: Early development experience informing current programs
- Novel programs: Next-generation amyloid targeting agents
- Stage: Discovery
- Focus: Selective targeting, reduced off-target effects
- HM30181: DOPA decarboxylase inhibitor
- Stage: Phase 1
- Partner: Pfizer collaboration
- Advantage: Improved pharmacokinetic properties
Hanmi's LUNA platform enables:
- Accelerated drug discovery through AI/ML
- Novel scaffold identification
- Efficient optimization of drug candidates
Kolon Life Science (콜론라이프사이언스)
Kolon Life Science (KOSPI: 102280) is a Korean biotechnology company focused on novel therapeutics, including gene therapy and biologics for neurodegenerative diseases[9].
Company Profile
| Attribute | Details |
|-----------|---------|
| Founded | 2000 |
| Headquarters | Seoul, South Korea |
| Focus | Gene therapy, cell therapy, novel biologics |
| Technology | Platform-based drug development |
Pipeline
Alzheimer's Disease
- KLS-101: Antibody therapy targeting amyloid
- Stage: Preclinical
- Mechanism: Monoclonal antibody against aggregated Aβ
- KLS-203: Tau-targeted immunotherapy
- Stage: Discovery
- Approach: Active vaccination against tau pathology
- KLS-301: Gene therapy for GDNF delivery
- Stage: Preclinical
- Target: Neurotrophic factor expression
- Delivery: AAV-mediated CNS gene delivery
Technology Platforms
Kolon has established key technology platforms:
- Gene therapy: AAV vector development, CNS targeting
- Cell therapy: Stem cell-based approaches
- Protein engineering: Antibody humanization, affinity maturation
Genexine (제넥신)
Genexine (KOSPI: 095700) is a Korean biotech company specializing in novel biologics, including long-acting therapeutics and immunotherapy[10].
Company Profile
| Attribute | Details |
|-----------|---------|
| Founded | 2006 |
| Headquarters | Seongnam, South Korea |
| Focus | Long-acting biologics, immunotherapy |
| Platform | HyFc fusion technology |
Pipeline
Neurodegeneration Programs
- GX-I7: Long-acting interferon beta
- Stage: Phase 2 (multiple indications)
- Application: Neuroinflammation in AD/PD
- GX-H9: Long-acting growth hormone
- Stage: Phase 2
- Research: Neuroprotective effects
- Novel programs: T-cell engaging antibodies
- Stage: Discovery
- Target: Immuno-oncology applications
Partnerships
Genexine has established international partnerships:
- Roche — Development collaboration
- STCube — Co-development agreements
- Various academic collaborations
Other Notable Companies
Chong Kun Dang Pharmaceutical (한국신약)
- Focus: CNS generic medications
- Products: Levodopa, carbidopa, donepezil generics
- Status: Established market presence
Dong-A ST (동아에스티)
- Focus: CNS, cardiovascular
- Programs: Parkinson's disease medications
- Pipeline: Generic and novel formulations
Yuhan Corporation (유한양행)
- Focus: CNS, metabolic diseases
- Programs: Novel antipsychotics, AD treatments
- Stage: Research and early development
Bukwang Pharmaceutical (부광약품)
- Focus: CNS, anti-infectives
- Programs: Levodopa formulations
- Status: Generic CNS portfolio
Korean Healthcare Ecosystem
Strengths and Advantages
South Korea offers several advantages for neurodegenerative drug development[1][4][5]:
| Area | Description | Advantage |
|------|-------------|-----------|
| Manufacturing | Strong CDMO and API capabilities | Cost-effective production, quality standards |
| Clinical trials | Efficient trial execution, rapid enrollment | Fast regulatory timelines |
| Technology | Advanced biotechnology, AI/ML integration | Accelerated discovery |
| Government support | Strong R&D incentives, regulatory support | Funding and policy alignment |
| Infrastructure | World-class hospitals, research institutions | Clinical trial excellence |
Clinical Research Infrastructure
Korean clinical trial infrastructure is highly developed:
- Academic medical centers: Seoul National University Hospital, Samsung Medical Center, Asan Medical Center
- Clinical research organizations: Local and global CRO presence
- Patient population: High prevalence of neurodegenerative diseases, treatment-naive populations
- Regulatory efficiency: MFDS provides efficient review processes
Government Initiatives
The Korean government actively supports pharmaceutical R&D:
MFDS Support Programs
- Pharmaceutical innovation support: R&D funding and tax incentives
- Clinical trial support: Infrastructure development, patient recruitment
- Regulatory harmonization: International alignment with FDA, EMA
- K-Bio strategy: National biotechnology development plan
Ministry of Trade, Industry and Energy
- Industrial technology R&D: Funding for novel drug development
- Global market expansion: Export support, market access
- Manufacturing excellence: Quality improvement programs
Academic Collaborations
Korean companies frequently collaborate with world-class academic institutions[11][12][13]:
Seoul National University (SNU)
- Brain Science Institute: Neurodegeneration research
- College of Medicine: Clinical research infrastructure
- Collaborations: Multiple industry partnerships
KAIST (Korea Advanced Institute of Science and Technology)
- Department of Bio and Brain Engineering: Drug discovery
- AI/ML integration: Accelerated identification of drug candidates
- Biotechnology research: Novel therapeutic modalities
Yonsei University
- College of Medicine: Neuroscience research
- Severance Hospital: Clinical trial execution
- Research collaboration: Industry partnerships
Korea University
- Neuroscience Institute: Basic research
- Neuropharmacology: Drug mechanism studies
Pipeline Overview
Alzheimer's Disease Programs
| Company | Target | Mechanism | Stage | Status |
|---------|--------|-----------|-------|--------|
| Daewoong | BACE1 | Amyloid production inhibition | Preclinical | IND-enabling |
| JW Pharmaceutical | Tau | Aggregation inhibitor | Discovery | Research |
| Hanmi Pharmaceutical | Amyloid | Next-gen targeting | Discovery | Early stage |
| Kolon Life Science | Amyloid | Antibody therapy | Preclinical | Development |
| Genexine | Inflammation | Immunomodulation | Phase 2 | Multiple indications |
Parkinson's Disease Programs
| Company | Target | Mechanism | Stage | Status |
|---------|--------|-----------|-------|--------|
| Daewoong | α-synuclein | Aggregation inhibitor | Discovery | Research |
| JW Pharmaceutical | A2A receptor | Antagonist | Phase 2 | Clinical |
| JW Pharmaceutical | DDC | Enzyme inhibition | Phase 1 | Clinical |
| Hanmi Pharmaceutical | DDC | Enzyme inhibition | Phase 1 | Clinical |
| Kolon Life Science | GDNF | Gene therapy | Preclinical | Development |
Investment Landscape
Korean biotech in neurodegeneration benefits from multiple factors[1][5]:
Investment Drivers
- Up to 40% R&D tax credit
- Direct grants for innovative drug development
- Rapid patient enrollment
- Quality data generation
- Licensing agreements
- Co-development collaborations
- Manufacturing partnerships
- Active Korean VC community
- Government-backed investment funds
- International investor interest
Market Opportunities
The Korean neurodegeneration market presents significant opportunities:
- Aging population: Increasing disease prevalence
- Unmet needs: Limited disease-modifying therapies
- Regulatory reform: Faster approval pathways
- Global partnerships: Access to international markets
Clinical Trials and Research
Ongoing Clinical Trials
Korea hosts numerous clinical trials for neurodegenerative diseases:
Alzheimer's Disease
- Multiple Phase 1/2 trials for novel mechanisms
- Immunotherapy programs in development
- Biomarker studies for patient selection
Parkinson's Disease
- A2A antagonist trials (JW Pharmaceutical)
- Novel dopamine agonists
- Gene therapy programs approaching clinical stage
Research Strengths
Korean research institutions contribute significantly to neurodegeneration science:
- Biomarker research: Early detection and diagnosis
- Neuroimaging: Advanced imaging techniques
- Genetics: Korean population genetic studies
- Stem cell research: Regenerative medicine approaches
Regulatory Environment
MFDS (Ministry of Food and Drug Safety)
The Korean regulatory framework supports efficient drug development[4]:
Approval Pathways
- Standard review: Standard timeline for standard drugs
- Fast track: Accelerated approval for innovative therapies
- Conditional approval: Early access for serious diseases
International Harmonization
- ICH compliance: Alignment with international standards
- FDA/EMA recognition: Mutual recognition where applicable
- Global submissions: Support for international filings
Quality Standards
Korean manufacturing meets international quality standards:
- US FDA: Multiple facility approvals
- EMA: European certification
- WHO: Prequalification for global markets
Competitive Landscape
Global Positioning
Korean companies occupy a growing position in the global pharmaceutical landscape:
| Category | Global Position | Strength |
|----------|-----------------|----------|
| Generic medications | Significant | Cost competition |
| Novel drug development | Emerging | Innovation capability |
| Biologics/Biosimilars | Growing | Manufacturing expertise |
| CDMO services | Strong | Quality and capacity |
International Competition
Korean companies compete with:
- Major pharma: Novartis, Roche, Eli Lilly, etc.
- Generic companies: Teva, Mylan, Sandoz
- Biotech: Emerging US/European biotechs
- Asian competitors: Indian, Chinese pharmaceutical companies
Competitive Advantages
Korean companies offer:
- Cost efficiency: Competitive manufacturing costs
- Quality: High quality standards, regulatory compliance
- Speed: Rapid clinical development
- Innovation: Growing R&D capabilities
Future Outlook
Growth Drivers
Several factors will shape the future of Korean neurodegeneration research:
Strategic Priorities
Korean companies are prioritizing:
Challenges and Opportunities
| Challenge | Opportunity |
|-----------|-------------|
| R&D funding | Government support programs |
| International competition | Differentiation through innovation |
| Regulatory complexity | Harmonization with global standards |
| Talent acquisition | Strong academic pipeline |
Korean Research Institutions
Key Research Centers
Seoul National University Brain Science Institute
- Focus: Neuroscience, neurodegeneration
- Capabilities: Basic research, animal models, clinical translation
- Collaboration: Multiple industry partnerships
KAIST Department of Bio and Brain Engineering
- Focus: Drug discovery, systems biology
- Capabilities: AI/ML for drug development
- Innovation: Novel target identification
Korea Institute of Science and Technology (KIST)
- Focus: Applied neuroscience research
- Capabilities: Translational research, drug development
- Partnerships: Industry collaborations
Research Strengths
Korean research institutions offer:
- Basic research: Strong neuroscience fundamentals
- Translational capability: Bridging discovery and development
- Clinical research: Well-organized clinical trial infrastructure
- Innovation: Novel approaches to neurodegeneration
Global Partnerships
International Collaborations
Korean companies have established numerous international partnerships:
Daewoong
- Licensing agreements with global pharma
- Co-development arrangements
- Manufacturing partnerships
JW Pharmaceutical
- Clinical development partnerships
- Technology licensing
Hanmi Pharmaceutical
- Global pharma collaborations
- Commercial partnerships
Market Access
Korean companies serve global markets:
- United States: Major market, FDA approvals
- Europe: EMA certifications, market access
- Asia: Regional expansion, emerging markets
- Global: 80+ country presence
Economic Impact
Healthcare Cost Savings
Korean pharmaceutical companies contribute significantly to healthcare affordability:
- Generic medications: Reducing treatment costs by 80-90%
- Local manufacturing: Supply chain efficiency
- Competitive pricing: Market-driven cost reduction
- Access improvement: Broader patient reach
Employment and Economic Activity
The pharmaceutical sector creates:
- Direct jobs: Research, manufacturing, commercial
- Indirect employment: Supply chain, distribution
- R&D investment: Technology development
- Export revenue: International market earnings
Sustainability and Corporate Responsibility
Environmental Practices
Korean pharmaceutical companies implement:
- Green manufacturing: Sustainable production processes
- Waste management: Environmental compliance
- Energy efficiency: Carbon footprint reduction
- Water conservation: Resource management
Social Responsibility
Companies contribute to:
- Healthcare access: Affordable medications
- Patient support: Disease awareness programs
- Education: Science and technology training
- Community health: Healthcare initiatives
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Pharmaceutical Companies](/companies/pharmaceutical)
- [Biotechnology](/topics/biotechnology)
- [Korean Pharmaceuticals](/companies/overview)
- [Amyloid-beta](/proteins/amyloid-beta-protein)
- [Tau](/proteins/tau)
- [Alpha-synuclein](/proteins/alpha-synuclein)
External Links
- [Korean Drug Development Portal](https://www.mfds.go.kr)
- [Korea Bio Council](https://www.koreabio.org)
- [Korea Pharmaceutical Manufacturers Association](https://www.kpma.or.kr)
- [MFDS Pharmaceutical Industry Support](https://www.mfds.go.kr)
References
<!-- expansion-work-done-2026-03-27 -->
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | companies-korean-neurodegeneration-biotech |
| kg_node_id | None |
| entity_type | company |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-75e4fe2feccb |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'companies-korean-neurodegeneration-biotech'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-companies-korean-neurodegeneration-biotech?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Korean Biotech Companies in Neurodegeneration](http://scidex.ai/artifact/wiki-companies-korean-neurodegeneration-biotech)
http://scidex.ai/artifact/wiki-companies-korean-neurodegeneration-biotech